Understanding how GasderminD affects severe lung injury
GasderminD regulation of Acute Lung Injury
This research aims to uncover how certain immune cells contribute to severe lung damage in conditions like Acute Respiratory Distress Syndrome, or ARDS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11118688 on NIH RePORTER |
What this research studies
Acute Respiratory Distress Syndrome (ARDS) causes severe lung damage, often leading to the loss of the lung's protective barrier and the death of lung cells. Currently, we don't fully understand how immune cells cause this damage, which means there are no effective treatments. This project explores a new idea: that specific immune cells called monocytes release a protein called GasderminD, which then causes lung cells to die. By understanding this process, we hope to find new ways to protect the lungs.
Who could benefit from this research
Good fit: This foundational research focuses on understanding the disease process, so it is most relevant to patients with Acute Respiratory Distress Syndrome (ARDS) or those at risk of severe lung injury.
Not a fit: Patients without acute lung injury or ARDS would not directly benefit from this specific research, as it focuses on the mechanisms of that condition.
Why it matters
Potential benefit: If successful, this work could lead to the development of new medications that specifically target the mechanisms causing lung cell death in ARDS, offering hope for more effective treatments.
How similar studies have performed: This project explores a novel pathway linking immune cells to lung cell death in ARDS, suggesting a new direction for treatment where current therapies are lacking.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Sarkar, Anasuya — Ohio State University
- Study coordinator: Sarkar, Anasuya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.